A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.

@article{Kakolyris2000ADS,
  title={A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.},
  author={Stylianos Souglakos John Kakolyris and John Souglakos and Sohia Agelaki and C H Kourousis and Dimitrios Mavroudis and Evanthia Sarra and Polychronis Malliotakis and Vassilis Georgoulias},
  journal={Lung cancer},
  year={2000},
  volume={30 3},
  pages={193-8}
}
PURPOSE A phase I study was conducted to determine the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of a CPT-11 plus cisplatin combination as salvage treatment in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Twenty-two patients with histologically confirmed NSCLC, who had failed taxotere-based… CONTINUE READING